← Back to Search

Metformin + Lifestyle Changes for Atrial Fibrillation (TRIM-AF Trial)

Phase 4
Waitlist Available
Led By Mina K Chung, MD
Research Sponsored by Mina Chung, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Paroxysmal AF, or persistent AF with plans for conversion.
No history of AF.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year, 2 years
Awards & highlights

TRIM-AF Trial Summary

This trial is testing whether metformin and lifestyle/risk factor modification can help prevent atrial fibrillation in people with pacemakers or defibrillators.

Who is the study for?
This trial is for adults with a pacemaker or ICD who've had at least one episode of atrial fibrillation in the past 3 months. They should not be on diabetes medication, have moderate renal disease, significant alcohol use, or life expectancy less than 2 years. Pregnant women and those unable to follow study protocols are also excluded.Check my eligibility
What is being tested?
The TRIM-AF study tests if Metformin and lifestyle changes can help manage Atrial Fibrillation in patients with cardiac devices. Participants will either get Metformin up to 750 mg twice daily or undergo lifestyle modifications, decided randomly.See study design
What are the potential side effects?
Metformin may cause digestive issues like nausea and diarrhea, as well as a rare but serious condition called lactic acidosis. Lifestyle changes typically don't have side effects but could include muscle soreness from new exercise routines.

TRIM-AF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have irregular heartbeats and plans to normalize it.
Select...
I have never had atrial fibrillation.
Select...
I am 18 years old or older.

TRIM-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year, 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year, 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in AF burden
Secondary outcome measures
%change in average AF time/day
AF ablation/pulmonary vein isolation (PVI) for increase in burden or persistent AF
AF density
+29 more

TRIM-AF Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Metformin + LRFMExperimental Treatment2 Interventions
Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
Group II: MetforminExperimental Treatment1 Intervention
Metformin ER up to 750 mg twice daily
Group III: Lifestyle/Risk Factor ModificationExperimental Treatment1 Intervention
Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
Group IV: ControlActive Control1 Intervention
Written educational literature on healthy eating and exercise guideline
Group V: No Atrial FibrillationActive Control1 Intervention
Written educational literature on healthy eating and exercise guideline
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Metformin
2006
Completed Phase 4
~2430

Find a Location

Who is running the clinical trial?

The Cleveland ClinicOTHER
1,026 Previous Clinical Trials
1,365,806 Total Patients Enrolled
22 Trials studying Atrial Fibrillation
5,441 Patients Enrolled for Atrial Fibrillation
Mina Chung, MDLead Sponsor
American Heart AssociationOTHER
324 Previous Clinical Trials
4,933,508 Total Patients Enrolled
11 Trials studying Atrial Fibrillation
92,067 Patients Enrolled for Atrial Fibrillation

Media Library

Lifestyle/Risk Factor Modification Clinical Trial Eligibility Overview. Trial Name: NCT03603912 — Phase 4
Atrial Fibrillation Research Study Groups: Lifestyle/Risk Factor Modification, Metformin, Control, No Atrial Fibrillation, Metformin + LRFM
Atrial Fibrillation Clinical Trial 2023: Lifestyle/Risk Factor Modification Highlights & Side Effects. Trial Name: NCT03603912 — Phase 4
Lifestyle/Risk Factor Modification 2023 Treatment Timeline for Medical Study. Trial Name: NCT03603912 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any recruitment opportunities for this clinical research?

"According to the clinical trial registry, this study is presently recruiting participants. The posting date for this research was August 24th 2018 and it has been updated as recently as December 4th 2021."

Answered by AI

For what health concerns is Lifestyle/Risk Factor Modification most often deployed?

"The therapeutic lifestyle/risk factor modification has a range of applications, notably treating exercise and the conditions type 1 diabetes mellitus, diabetic ketoacidosis, polycystic ovary syndrome."

Answered by AI

To what extent is Lifestyle/Risk Factor Modification beneficial for patients?

"This Phase 4 trial has generated enough evidence for the safety of Lifestyle/Risk Factor Modification to be rated as a 3 on Power's scale."

Answered by AI

Have past research efforts explored the impact of Lifestyle/Risk Factor Modification?

"Currently, 170 ongoing clinical trials are researching the effects of Lifestyle/Risk Factor Modification with 43 of them in their final stage. Pittsburgh Pennsylvania is just one out of 1903 sites that have approved trials regarding this subject."

Answered by AI

How many participants are involved in this clinical trial?

"Affirmative. The listing on clinicaltrials.gov reveals that this research is presently recruiting participants, which was first posted on August 24th 2018 and updated on December 4th 2021. 270 individuals are needed to be enrolled from a single medical facility."

Answered by AI
~49 spots leftby Aug 2025